Woori Bank to Provide 1 Trillion Won in Financial Support to Chong Kun Dang
Establishment of R&D Complex in Baegot District, Siheung
Expansion of Global New Drug Pipeline
Support for Mid- to Long-Term Investment
Woori Bank will provide financial support of 1 trillion won over the next five years to Chong Kun Dang Pharmaceutical Corp. for new drug research and development (R&D) and the expansion of its global production bases. The plan is to expand productive finance for advanced strategic industries by establishing a credit line that preemptively reflects the large-scale investment demand of the bio industry.
(Photo right) Jinwan Jung, President of Woori Bank, and (left) Youngjoo Kim, CEO of Chong Kun Dang, are posing for a commemorative photo after signing a business agreement at Woori Bank headquarters on the 26th. Courtesy of Woori Bank.
View original imageOn May 26, Woori Bank announced that it had signed a financial support agreement with Chong Kun Dang Pharmaceutical Corp. at its headquarters in Jung-gu, Seoul, to strengthen the competitiveness of the advanced bio industry. The signing ceremony was attended by Jinwan Jung, CEO of Woori Bank, Youngjoo Kim, CEO of Chong Kun Dang Pharmaceutical Corp., and other key executives from both companies. Through this agreement, the two sides have established a total financial support limit of 1 trillion won for the next five years and agreed to build a mid- to long-term cooperation system. Woori Bank plans to support Chong Kun Dang’s investment plans, including new drug development and R&D investment, the establishment of research and production infrastructure, trade and overseas business financing, and mutually beneficial finance for partner companies.
Chong Kun Dang is pushing forward with the establishment of an advanced biopharmaceutical complex R&D cluster in the Baegot district of Siheung, Gyeonggi Province, to strengthen its global competitiveness. At the same time, the company is expanding its global new drug pipeline and reinforcing its overseas research and business bases, thereby broadening its foundation for future growth.
A key feature of this agreement is that the credit line was set in advance to reflect Chong Kun Dang’s future investment needs. This is expected to enhance the speed, stability, and predictability of funding execution, reduce burdens arising from changes in the financial environment, and enable the company to focus on long-term R&D and global business expansion.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Jinwan Jung, CEO of Woori Bank, stated, “Chong Kun Dang is a leading Korean bio company that is enhancing its R&D capabilities and global competitiveness around the Baegot R&D cluster. Through this agreement, Woori Bank will faithfully fulfill its financial role to ensure that Chong Kun Dang’s R&D and global ambitions bear fruit, and we will stand as a strong partner in the industry’s growth.” Woori Bank plans to continue expanding productive finance that connects advanced strategic industries and real-economy investment, supporting the strengthening of national industrial competitiveness and laying the foundation for future growth.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.